Should systemic thrombolytic therapy be considered a first-line treatment in acute pulmonary embolism? ( Author`s Reply )

References (1)

1. Aykan AC, Boyacı F, Hatem E. Successful treatment of a pulmonary embolism with low dose prolonged infusion of tissue typed plasminogen activator in a 37 year old female in early postoperative period. Anadolu Kardiyol Derg 2014; 14: 400-2. [CrossRef] 2. Jaff MR, McMurtry MS, Archer SL, Cushman M, Goldenberg N, Goldhaber SZ, et al. American Heart Association Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation; American Heart Association Council on Peripheral Vascular Disease; American Heart Association Council on Arteriosclerosis, Thrombosis and Vascular Biology. Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association. Circulation 2011; 123: 1788-830. [CrossRef] 3. Özkan M, Gündüz S, Biteker M, Astarcıoğlu MA, Çevik C, Kaynak E, et al. Comparison of Different TEE-guided thrombolytic regimens for prosthetic valve thrombosis: The TROIA Trial. JACC Cardiovasc Imaging 2013; 6: 206-16. [CrossRef] 4. Engelhardt TC, Taylor AJ, Simprini LA, Kucher N. Catheter-directed ultrasound-accelerated thrombolysis for the treatment of acute pulmonary embolism. Thromb Res 2011; 128: 149-54. [CrossRef] 5. Aykan AC, Gökdeniz T, Gül I, Kalaycıoğlu E, Boyacı F, Hatem E, et al. Low dose prolonged infusion of tissue type plasminogen activator therapy in massive pulmonary embolism. European Heart J 2014; 35 (Suppl 1): 69.